Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 20888992

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2010 Oct 2
First author
de Bono JS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2010 Oct 2;376(9747):1119-20. doi: 10.1016/S0140-6736(10)61510-3.
    note
    Source null
    related pmid
    20888974
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2010 Dec;7(12):645. doi: 10.1038/nrurol.2010.200.
    note
    Source null
    related pmid
    21188774
    relationship
    Comment in
  3. citation
    Lancet. 2011 Jan 8;377(9760):121-2; author reply 122-3. doi: 10.1016/S0140-6736(11)60013-5.
    note
    Source null
    related pmid
    21215875
    relationship
    Comment in
  4. citation
    Lancet. 2011 Jan 8;377(9760):121; author reply 122-3. doi: 10.1016/S0140-6736(11)60012-3.
    note
    Source null
    related pmid
    21215876
    relationship
    Comment in
  5. citation
    Eur Urol. 2011 Apr;59(4):658. doi: 10.1016/j.eururo.2011.01.021.
    note
    Source null
    related pmid
    21414886
    relationship
    Comment in
  6. citation
    Eur Urol. 2011 Apr;59(4):659. doi: 10.1016/j.eururo.2011.01.022.
    note
    Source null
    related pmid
    21414888
    relationship
    Comment in
  7. citation
    Nat Rev Clin Oncol. 2010 Dec;7(12):671. doi: 10.1038/nrclinonc.2010.177.
    note
    Source null
    related pmid
    21542197
    relationship
    Comment in

Authors and identifiers

  1. name
    de Bono JS
    type
    Author
  2. name
    Oudard S
    type
    Author
  3. name
    Ozguroglu M
    type
    Author
  4. name
    Hansen S
    type
    Author
  5. name
    Machiels JP
    type
    Author
  6. name
    Kocak I
    type
    Author
  7. name
    Gravis G
    type
    Author
  8. name
    Bodrogi I
    type
    Author
  9. name
    Mackenzie MJ
    type
    Author
  10. name
    Shen L
    type
    Author
  11. name
    Roessner M
    type
    Author
  12. name
    Gupta S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    de Bono JS
    type
    Author
  2. name
    Oudard S
    type
    Author
  3. name
    Ozguroglu M
    type
    Author
  4. name
    Hansen S
    type
    Author
  5. name
    Machiels JP
    type
    Author
  6. name
    Kocak I
    type
    Author
  7. name
    Gravis G
    type
    Author
  8. name
    Bodrogi I
    type
    Author
  9. name
    Mackenzie MJ
    type
    Author
  10. name
    Shen L
    type
    Author
  11. name
    Roessner M
    type
    Author
  12. name
    Gupta S
    type
    Author
bibliography ids
  1. nci-bib-d141c27263b5a93387fe43ca
book metadata
content sha256
256d8c7a16662762182dbce7e2985cec7cca034490cf549a1f4127c601654581
document type
citation
dois
  1. 10.1016/S0140-6736(10)61389-X
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:20888992
immutable id
pubmed:20888992@256d8c7a16662762182dbce7e2985cec7cca034490cf549a1f4127c601654581
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9747
name
Lancet (London, England)
nlm unique id
2985213R
pages
1147-54
volume
376
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2010 Oct 2;376(9747):1119-20. doi: 10.1016/S0140-6736(10)61510-3.
    note
    Source null
    related pmid
    20888974
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2010 Dec;7(12):645. doi: 10.1038/nrurol.2010.200.
    note
    Source null
    related pmid
    21188774
    relationship
    Comment in
  3. citation
    Lancet. 2011 Jan 8;377(9760):121-2; author reply 122-3. doi: 10.1016/S0140-6736(11)60013-5.
    note
    Source null
    related pmid
    21215875
    relationship
    Comment in
  4. citation
    Lancet. 2011 Jan 8;377(9760):121; author reply 122-3. doi: 10.1016/S0140-6736(11)60012-3.
    note
    Source null
    related pmid
    21215876
    relationship
    Comment in
  5. citation
    Eur Urol. 2011 Apr;59(4):658. doi: 10.1016/j.eururo.2011.01.021.
    note
    Source null
    related pmid
    21414886
    relationship
    Comment in
  6. citation
    Eur Urol. 2011 Apr;59(4):659. doi: 10.1016/j.eururo.2011.01.022.
    note
    Source null
    related pmid
    21414888
    relationship
    Comment in
  7. citation
    Nat Rev Clin Oncol. 2010 Dec;7(12):671. doi: 10.1038/nrclinonc.2010.177.
    note
    Source null
    related pmid
    21542197
    relationship
    Comment in
outcomes validated
false
pmid
20888992
provenance
batch id
10a38257e12e9ed1867a
provider
NCBI PubMed ESummary
record sha256
c305a5225dd7594f501226a91582f2293befc835dd546c540760b0583530246f
response sha256
84c4808ca38b35d999cfdf809eb088835175ab38d71586c626096d677096bbcc
retrieved at
2026-09-09T23:46:35.793530+00:00
publication date
display
2010 Oct 2
precision
day
year
2010
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/20888992/
title
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Preserved source evidence · Not medical advice